Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Decreased absolute numbers of CD3+ T cells and CD8+ T cells during aging in herpes zoster patients.

Wei L, Zhao J, Wu W, Zhang Y, Fu X, Chen L, Wang X.

Sci Rep. 2017 Nov 8;7(1):15039. doi: 10.1038/s41598-017-15390-w.

2.

Parasite Infection, Carcinogenesis and Human Malignancy.

van Tong H, Brindley PJ, Meyer CG, Velavan TP.

EBioMedicine. 2017 Feb;15:12-23. doi: 10.1016/j.ebiom.2016.11.034. Epub 2016 Dec 2. Review.

3.

The Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development.

Hartlage AS, Liu T, Patton JT, Garman SL, Zhang X, Kurt H, Lozanski G, Lustberg ME, Caligiuri MA, Baiocchi RA.

Cancer Immunol Res. 2015 Jul;3(7):787-94. doi: 10.1158/2326-6066.CIR-14-0242. Epub 2015 Mar 3.

4.

Epstein-Barr virus latent membrane protein 1 genetic variability in peripheral blood B cells and oropharyngeal fluids.

Renzette N, Somasundaran M, Brewster F, Coderre J, Weiss ER, McManus M, Greenough T, Tabak B, Garber M, Kowalik TF, Luzuriaga K.

J Virol. 2014 Apr;88(7):3744-55. doi: 10.1128/JVI.03378-13. Epub 2014 Jan 15.

5.

MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response.

Long HM, Chagoury OL, Leese AM, Ryan GB, James E, Morton LT, Abbott RJ, Sabbah S, Kwok W, Rickinson AB.

J Exp Med. 2013 May 6;210(5):933-49. doi: 10.1084/jem.20121437. Epub 2013 Apr 8.

6.

Distinct kinetics of Gag-specific CD4+ and CD8+ T cell responses during acute HIV-1 infection.

Riou C, Ganusov VV, Campion S, Mlotshwa M, Liu MK, Whale VE, Goonetilleke N, Borrow P, Ferrari G, Betts MR, Haynes BF, McMichael AJ, Gray CM.

J Immunol. 2012 Mar 1;188(5):2198-206. doi: 10.4049/jimmunol.1102813. Epub 2012 Jan 27.

7.

Progress and problems in understanding and managing primary Epstein-Barr virus infections.

Odumade OA, Hogquist KA, Balfour HH Jr.

Clin Microbiol Rev. 2011 Jan;24(1):193-209. doi: 10.1128/CMR.00044-10. Review.

8.

Programmed Death-1 expression on Epstein Barr virus specific CD8+ T cells varies by stage of infection, epitope specificity, and T-cell receptor usage.

Greenough TC, Campellone SC, Brody R, Jain S, Sanchez-Merino V, Somasundaran M, Luzuriaga K.

PLoS One. 2010 Sep 23;5(9):e12926. doi: 10.1371/journal.pone.0012926.

9.

Urea-mediated cross-presentation of soluble Epstein-Barr virus BZLF1 protein.

Barabas S, Gary R, Bauer T, Lindner J, Lindner P, Weinberger B, Jilg W, Wolf H, Deml L.

PLoS Pathog. 2008 Nov;4(11):e1000198. doi: 10.1371/journal.ppat.1000198. Epub 2008 Nov 7.

10.

Detailed analysis of Epstein-Barr virus-specific CD4+ and CD8+ T cell responses during infectious mononucleosis.

Scherrenburg J, Piriou ER, Nanlohy NM, van Baarle D.

Clin Exp Immunol. 2008 Aug;153(2):231-9. doi: 10.1111/j.1365-2249.2008.03699.x. Epub 2008 Jun 28.

11.

Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines.

Bhaduri-McIntosh S, Rotenberg MJ, Gardner B, Robert M, Miller G.

Blood. 2008 Feb 1;111(3):1334-43. Epub 2007 Oct 17.

12.

Human CD4+ T cell epitopes from vaccinia virus induced by vaccination or infection.

Calvo-Calle JM, Strug I, Nastke MD, Baker SP, Stern LJ.

PLoS Pathog. 2007 Oct 12;3(10):1511-29.

13.

Infection of CD127+ (interleukin-7 receptor+) CD4+ cells and overexpression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection.

Zaunders JJ, Ip S, Munier ML, Kaufmann DE, Suzuki K, Brereton C, Sasson SC, Seddiki N, Koelsch K, Landay A, Grey P, Finlayson R, Kaldor J, Rosenberg ES, Walker BD, Fazekas de St Groth B, Cooper DA, Kelleher AD.

J Virol. 2006 Oct;80(20):10162-72.

14.

CD127+CCR5+CD38+++ CD4+ Th1 effector cells are an early component of the primary immune response to vaccinia virus and precede development of interleukin-2+ memory CD4+ T cells.

Zaunders JJ, Dyer WB, Munier ML, Ip S, Liu J, Amyes E, Rawlinson W, De Rose R, Kent SJ, Sullivan JS, Cooper DA, Kelleher AD.

J Virol. 2006 Oct;80(20):10151-61.

15.

Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.

Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm GW, Mautner J.

J Exp Med. 2006 Apr 17;203(4):995-1006. Epub 2006 Mar 20.

16.

Selection of Epstein-Barr virus specific cytotoxic T lymphocytes can be performed with B lymphoblastoid cell lines created in serum-free media.

Gallot G, Vollant S, Vivien R, Clémenceau B, Ferrand C, Tiberghien P, Gaschet J, Robillard N, Vié H.

Clin Exp Immunol. 2006 Apr;144(1):158-68.

17.

Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot"

Bihl FK, Loggi E, Chisholm JV 3rd, Hewitt HS, Henry LM, Linde C, Suscovich TJ, Wong JT, Frahm N, Andreone P, Brander C.

J Transl Med. 2005 May 11;3(1):20.

18.

HLA-restricted epitope identification and detection of functional T cell responses by using MHC-peptide and costimulatory microarrays.

Stone JD, Demkowicz WE Jr, Stern LJ.

Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3744-9. Epub 2005 Feb 23.

19.

Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection.

Amyes E, Hatton C, Montamat-Sicotte D, Gudgeon N, Rickinson AB, McMichael AJ, Callan MF.

J Exp Med. 2003 Sep 15;198(6):903-11.

Supplemental Content

Support Center